Tandem Diabetes Care Stock Market Capitalization
| TNDM Stock | USD 35.34 0.86 2.38% |
Tandem Diabetes Care fundamentals help investors to digest information that contributes to Tandem Diabetes' financial success or failures. It also enables traders to predict the movement of Tandem Stock. The fundamental analysis module provides a way to measure Tandem Diabetes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tandem Diabetes stock.
| Last Reported | Projected for Next Year | ||
| Market Cap | 1.7 B | 1.8 B |
Tandem | Market Capitalization |
Tandem Diabetes Care Company Market Capitalization Analysis
Tandem Diabetes' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Tandem Diabetes Market Capitalization | 2.37 B |
Most of Tandem Diabetes' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tandem Diabetes Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tandem Market Capitalization Driver Correlations
Understanding the fundamental principles of building solid financial models for Tandem Diabetes is extremely important. It helps to project a fair market value of Tandem Stock properly, considering its historical fundamentals such as Market Capitalization. Since Tandem Diabetes' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tandem Diabetes' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tandem Diabetes' interrelated accounts and indicators.
Click cells to compare fundamentals
Tandem Market Capitalization Historical Pattern
Today, most investors in Tandem Diabetes Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tandem Diabetes' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's market capitalization growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Tandem Diabetes market capitalization as a starting point in their analysis.
Tandem Diabetes Market Capitalization |
| Timeline |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Tandem Long Term Debt To Capitalization
Long Term Debt To Capitalization |
|
Based on the recorded statements, the market capitalization of Tandem Diabetes Care is about 2.37 B. This is 81.7% lower than that of the Health Care Equipment & Supplies sector and 78.59% lower than that of the Health Care industry. The market capitalization for all United States stocks is 87.55% higher than that of the company.
Tandem Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tandem Diabetes' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tandem Diabetes could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics of similar companies.Tandem Diabetes is currently under evaluation in market capitalization category among related companies.
Tandem Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.0963 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 2.36 B | ||||
| Shares Outstanding | 64.56 M | ||||
| Shares Owned By Insiders | 0.64 % | ||||
| Shares Owned By Institutions | 99.36 % | ||||
| Number Of Shares Shorted | 9.24 M | ||||
| Price To Earning | 494.25 X | ||||
| Price To Book | 6.90 X | ||||
| Price To Sales | 2.89 X | ||||
| Revenue | 747.72 M | ||||
| Gross Profit | 412.99 M | ||||
| EBITDA | (118.22 M) | ||||
| Net Income | (222.61 M) | ||||
| Cash And Equivalents | 608.73 M | ||||
| Cash Per Share | 9.47 X | ||||
| Total Debt | 415.67 M | ||||
| Debt To Equity | 1.00 % | ||||
| Current Ratio | 4.80 X | ||||
| Book Value Per Share | 4.78 X | ||||
| Cash Flow From Operations | (31.81 M) | ||||
| Short Ratio | 6.31 X | ||||
| Earnings Per Share | (3.43) X | ||||
| Target Price | 38.64 | ||||
| Number Of Employees | 2.4 K | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 2.37 B | ||||
| Total Asset | 952.66 M | ||||
| Retained Earnings | (951.8 M) | ||||
| Working Capital | 552.73 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 26.52 M | ||||
| Net Asset | 952.66 M |
About Tandem Diabetes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:Check out Tandem Diabetes Piotroski F Score and Tandem Diabetes Altman Z Score analysis. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (3.43) | Revenue Per Share 11.509 | Quarterly Revenue Growth (0.11) | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.